Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostaglandin D₂ receptor 2 (CRTH2), also known as DP2, is a G protein-coupled receptor that binds prostaglandin D₂ (PGD₂). It is highly expressed on Th2 lymphocytes, eosinophils, and basophils and mediates their chemotaxis and activation. CRTH2 plays a central role in allergic inflammation and is a therapeutic target for allergic diseases like asthma and atopic dermatitis. Activation of CRTH2 leads to decreased cAMP levels, increased intracellular calcium, and activation of the PI3K-AKT-GSK/NFAT axis.
CRTH2 antagonism; blocking the binding of PGD₂ to CRTH2, inhibiting downstream signaling and cellular recruitment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin D₂ receptor 2 (CRTH2).